Synthesis of 1,3,4-Thiadiazolo[2′,3′:2,3]imidazo[4,5-b]indoles

Behzad Jafari; Sayfidin Safarov; Muattar Khalikova; Peter Ehlers; Peter Langer

doi:10.1055/s-0039-1690147

Synlett, Table of Contents

Synlett 2019; 30(15): 1791-1794
DOI: 10.1055/s-0039-1690147

letter

Synthesis of 1,3,4-Thiadiazolo[2′,3′:2,3]imidazo[4,5-b]indoles

Behzad Jafari

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany Email: peter.langer@uni-rostock.de

,

Sayfidin Safarov

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany Email: peter.langer@uni-rostock.de

^bInstitute of Chemistry, Tajikistan Academy of Sciences, ul. Aini 299, Dushanbe, 734063, Tajikistan

,

Muattar Khalikova

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany Email: peter.langer@uni-rostock.de

^bInstitute of Chemistry, Tajikistan Academy of Sciences, ul. Aini 299, Dushanbe, 734063, Tajikistan

,

Peter Ehlers

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany Email: peter.langer@uni-rostock.de

,

Peter Langer∗

^aInstitut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany Email: peter.langer@uni-rostock.de

^cLeibniz Institut für Katalyse an der Universität Rostock e.V. (LIKAT), Albert-Einstein-Str. 29a, 18059 Rostock, Germany

› Author Affiliations

Abstract

All articles of this category

Abstract

Hitherto unknown thiadiazolo[2′,3′:2,3]imidazo[4,5-b]indoles were synthesized for the first time by base-mediated cyclocondensation, bromination, and subsequent cyclization by two-fold Buchwald–Hartwig reactions.

Key words

Buchwald–Hartwig reaction - cyclizations - imidazothiazoles - palladium

Full Text

References

References and Notes

1a Gadad AK, Mahajanshetti CS, Nimbalkar S, Raichurkar A. Eur. J. Med. Chem. 2000; 35: 853
1b Ramprasad J, Nayak N, Dalimba U, Yogeeswari P, Sriram D, Peethambar SK, Achur R, Kumar HS. S. Eur. J. Med. Chem. 2015; 95: 49
1c Ibraheem H, Al-Majedy Y, Al-Amiery A. Syst. Rev. Pharm. 2018; 9: 36

2 Alwan WS, Karpoormath R, Palkar MB, Patel HM, Rane RA, Shaikh MS, Kajee A, Mlisana KP. Eur. J. Med. Chem. 2015; 95: 514

3a Kolavi G, Hegde V, Khazi IA. Tetrahedron Lett. 2006; 47: 2811
3b Hegde VS, Kolavi GD, Lamani RS, Khazi IA. M. J. Sulfur Chem. 2006; 27: 553

4a Gadad AK, Palkar MB, Anand K, Noolvi MN, Boreddy TS, Wagwade J. J. Bioorg. Med. Chem. 2008; 16: 276
4b Cristina A, Leonte D, Vlase L, Bencze LC, Imre S, Marc G, Apan B, Mogosan C, Zaharia V. Molecules 2018; 23: 2425

5a Elkis Y, Cohen M, Yaffe E, Satmary-Tusk S, Feldman T, Hikri E, Nyska A, Feiglin A, Ofran Y, Shpungin S, Nir U. Nat. Commun. 2017; 8: 940
5b Kumar R, Bua S, Ram S, De Prete S, Capaso C, Supuran CT, Sharma PK. Bioorg. Med. Chem. 2017; 25: 1286
5c Patel HM, Sing B, Bhardwaj V, Palkar M, Shaikh MS, Rane R, Alwan WS, Gadad AK, Noolvi MN, Karpoormath R. Eur. J. Med. Chem. 2015; 93: 599
5d Kamal A, Rao AV. S, Reddy TS, Polepalli S, Shaik SP, Bagul C, Vishnuvardhan MV. P. S, Jain N. Med. Chem. Commun. 2015; 6: 1842

6a Temple KJ, Duvernay MT, Young SE, Wen W, Wu W, Maeng JG, Blobaum AL, Stauffer SR, Hamm HE, Lindsley CW. J. Med. Chem. 2016; 59: 7690
6b Chen P, Ren S, Song H, Chen C, Chen F, Xu Q, Kong Y, Sun H. Bioorg. Med. Chem. 2019; 27: 116

7 Khazi IA. M, Gadad AK, Lamani RS, Bhongade BA. Tetrahedron 2011; 67: 3289 ; and references cited therein

8a Copin C, Henry N, Buron F, Routier S. Eur. J. Org. Chem. 2012; 3079
8b Copin C, Massip S, Léger J.-M, Jarry C, Buron F, Routier S. Eur. J. Org. Chem. 2015; 6932
8c Copin C, Buron F, Routier S. Eur. J. Org. Chem. 2016; 1958
8d Copin C, Henry N, Buron F, Routier S. Synlett 2016; 27: 1091

9a Janke J, Ehlers P, Villinger A, Langer P. Synlett 2019; 30: 817
9b Do HH, Janke J, Amirjanyan A, Ghochikyan T, Flader A, Villinger A, Ehlers P, Lochbrunner S, Surkus A.-E, Langer P. Org. Biomol. Chem. 2018; 16: 6543
9c Salman GA, Janke S, Pham NN, Ehlers P, Langer P. Tetrahedron 2018; 74: 1024 ; and references cited therein

10a Jafari B, Rashid F, Safarov S, Ospanov M, Yelibayeva N, Abilov ZA, Turmukhanova MZ, Kalugin SN, Ehlers P, Umar MI, Zaib S, Iqbal J, Langer P. ChemistrySelect 2018; 3: 12213
10b Jafari B, Ospanov M, Yelibayeva N, Ejaz SA, Khan SU, Amjad ST, Safarov S, Abilov ZA, Turmukhanova MZ, Kalugin SN, Ehlers P, Lecka J, Sévigny J, Iqbal J, Langer P. Eur. J. Med. Chem. 2018; 144: 116
10c Jafari B, Yelibayeva N, Ospanov M, Ejaz SA, Afzal S, Khan SU, Abilov ZA, Turmukhanova MZ, Kalugin SN, Safarov S, Lecka J, Sévigny J, Raman Q, Ehlers P, Iqbal J, Langer P. RSC Adv. 2016; 6: 107556
10d Jafari B, Jalil S, Zaib S, Safarov S, Khalikova M, Ospanov M, Yelibayeva N, Abilov ZA, Turmukhanova MZ, Kalugin SN, Ehlers P, Iqbal J, Langer P. ChemistrySelect 2019; 4: 7284

11 Safarov S, Rahmon R, Kukaniev MA, Schollmeyer D, Karpuk E, Meier H. J. Heterocycl. Chem. 2008; 45: 299
12 General Procedure A for the Synthesis of 6-(2-Bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (3) 2-Amino-5-ethyl-1,3,4-thiadiazole (1.70 g, 13 mmol) and 2,2′-dibromoacetophenone (1.88 g, 6.8 mmol) were dissolved in n-butanol (50 mL). Afterwards, the reaction mixture was heated to reflux for 8 h. After cooling to room temperature, the crude compound was purified by flash column chromatography on silica gel (ethyl acetate/heptane).
13 6-(2-Bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (3) According to procedure A, product 3 (1.76 g, 84%) was isolated as a brownish solid; mp 110–112 °C. IR (ATR): ν = 3140 (w), 3069 (w), 2962 (w), 2869 (w), 1688 (m), 1608 (m), 1520 (s), 1445 (m), 1376 (m), 1261 (m), 1182 (s), 1015 (s), 938 (w), 853 (s), 759 (s) cm^–1. ¹H NMR (300 MHz, CDCl₃): δ = 8.39 (s, 1 H, CH_Ar), 8.01 (dd, ³ J = 7.9 Hz, ⁴ J = 1.9 Hz, 1 H, CH_Ar), 7.63 (dd, ³ J = 7.9 Hz, ⁴ J = 1.5 Hz, 1 H, CH_Ar), 7.34–7.39 (m, 1 H, CH_Ar), 7.10–7.16 (m, 1 H, CH_Ar), 3.01 (q, ³ J = 7.45 Hz, 2 H, CH₂), 1.43 (t, ³ J = 7.53 Hz, 3 H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ = 166.3 (C_Ar), 144.6 (C_Ar), 143.3 (C_Ar), 134.5 (C_Ar), 133.9 (CH_Ar), 130.9 (CH_Ar), 128.7 (CH_Ar), 127.7 (CH_Ar), 121.0 (C_Ar), 113.4 (CH_Ar), 25.9 (CH₂), 13.1 (CH₃). MS (EI, 70 ev): m/z = 309 (77) [M]⁺, 307 (77) [M]⁺, 227 (29), 277 (40), 225 (28), 183 (32), 181 (32), 173 (52), 146 (100), 120 (5), 114 (7), 102 (41). HRMS: m/z calcd for C₁₂H₁₀N₃ ⁸¹BrS: 308.97529; found: 308.97518. HRMS: m/z calcd for C₁₂H₁₀N₃BrS: 306.97773; found: 306.97720.
14 General Procedure B for the Synthesis of 5-Bromo-6-(2-bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (4) 6-(2-Bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (3; 1.40 g, 3.6 mmol) dissolved in acetic acid (15 mL) and bromine (0.26 mL) dissolved in acetic acid (1.5 mL) were added dropwise at ambient temperature over 15 min. The reaction was vigorously stirred for 75 min. A saturated aqueous solution of NaOAc (410 mg, 5 mmol) was slowly added with cooling, the precipitate formed was collected by filtration, and the crude compound was purified by flash column chromatography on silica gel (ethyl acetate/heptane).
15 5-Bromo-6-(2-bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (4) According to procedure B, product 4 (1.35 g, 76%) was isolated as a yellow solid; mp 109–110 °C. IR (ATR): ν = 2979 (w), 2934 (w), 2915 (w), 1594 (w), 1524 (m), 1467 (s), 1426 (m), 1322 (m), 1284 (w), 1106 (s), 1044 (s), 977 (s), 754 (s), 724 (s), 669 (m), 638 (s) cm^–1. ¹H NMR (300 MHz, CDCl₃): δ = 7.69 (d, ³ J = 8.1 Hz, 1 H, CH_Ar), 7.47 (d, ³ J = 7.5 Hz, 1 H, CH_Ar), 7.38 (d, ³ J = 7.3 Hz, 1 H, CH_Ar), 7.28 (d, ³ J = 7.7 Hz, 1 H, CH_Ar), 3.09 (q, ³ J = 7.5 Hz, 2 H, CH₂), 1.46 (t, ³ J = 7.8 Hz, 3 H, CH₃). ¹³C NMR (62 MHz, DMSO): δ = 168.0 (C_Ar), 143.4 (C_Ar), 142.2 (C_Ar), 133.7 (C_Ar), 132.8 (CH_Ar), 132.4 (CH_Ar), 130.6 (CH_Ar), 127.5 (CH_Ar), 123.1 (C_Ar), 94.8 (C_Ar), 25.0 (CH₂), 12.8 (CH₃). MS (EI, 70 ev): m/z = 389 (35) [M]⁺, 387 (66) [M]⁺, 385 (33) [M]⁺, 253 (100), 251 (98), 226 (9), 201 (6), 172 (16), 151 (15), 149 (14), 146 (15), 128 (16), 120 (28), 102 (17). HRMS: m/z calcd for C₁₂H₉N₃Br₂S: 384.88784; found: 384.88737. HRMS: m/z calcd for C₁₂H₉N₃Br⁸¹BrS: 386.88580; found: 386.88539. HRMS: m/z calcd for C₁₂H₉N₃ ⁸¹Br₂S: 384.88375; found: 388.88329.
16 General Procedure C for the Synthesis of 2-Ethyl-5-(substituted)-5H-[1,3,4]thiadiazolo[2′,3′:2,3]imidazo[4,5-b]indole 5a–g 5-Bromo-6-(2-bromophenyl)-2-ethyl-imidazo[2,1-b]-1,3,4-thiadiazole (4, 100 mg, 0.275 mmol), aniline derivative (0.412 mmol), Pd₂(dba)₃ (0.025 mmol), XantPhos (0.0750 mmol), NaOt-Bu (0.750 mmol) were heated in dry xylene (2 mL) at 150 °C for 24 h. After cooling to room temperature, the reaction was diluted with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent evaporated. The crude compound was purified by flash column chromatography on silica gel (ethyl acetate/heptane).
17 2-Ethyl-5-(p-tolyl)-5H-[1,3,4]thiadiazolo[2′,3′:2,3]-imidazo[4,5-b]indole (5a) According to procedure C, using p-toluidine, product 5a (73 mg, 84%) was isolated as a brown solid; mp 187–188 °C. IR (ATR): ν = 3034 (w), 2980 (w), 2939 (w), 2872 (w), 1606 (m), 1537 (m), 1513 (s), 1436 (m), 1380 (m), 1259 (s), 1186 (m), 1081 (w), 970 (w), 888 (w), 797 (s), 749 (m), 736 (s) cm^–1. ¹H NMR (300 MHz, CDCl₃): δ = 7.96–8.01 (m, 1 H, CH_Ar), 7.60–7.63 (m, 1 H, CH_Ar), 7.55 (d, ³ J = 8.4 Hz, 2 H, CH_Ar), 7.38 (d, ³ J = 8.5 Hz, 2 H, CH_Ar), 7.26–7.30 (m, 2 H, CH_Ar), 3.01 (q, ³ J = 7.6 Hz, 2 H, CH₂), 2.47 (s, 3 H, CH₃), 1.41 (t, ³ J = 7.6 Hz, 3 H, CH₃). ¹³C NMR (75 MHz, CDCl₃): δ = 164.5 (C_Ar), 144.0 (C_Ar), 138.7 (C_Ar), 136.9 (C_Ar), 134.1 (C_Ar), 131.3 (C_Ar), 130.3 (CH_Ar), 125.0 (CH_Ar), 122.8 (CH_Ar), 121.3 (CH_Ar), 120.3 (C_Ar), 119.3 (C_Ar), 118.6 (CH_Ar), 111.4 (CH_Ar), 26.0 (CH₂), 21.4 (CH₃), 13.3 (CH₃). MS (EI, 70 ev): m/z = 332 (93) [M]⁺, 278 (10), 277 (40), 276 (100), 263 (9), 262 (50), 250 (5), 219 (36), 166 (8), 138 (26), 102 (12). HRMS: m/z calcd for C₁₉H₁₆N₄S: 332.10902; found: 332.10875.

Supplementary Material

Supporting Information